Faber, Anthony C <br/><br/>
BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors.  [electronic resource] 

 -  Cancer discovery  Sep 2011 
 - 352-65 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2159-8290 
<br/><br/><label>Standard No.: </label>10.1158/2159-8290.CD-11-0106  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Apoptosis--drug effects<br/>Apoptosis Regulatory Proteins--biosynthesis<br/>BH3 Interacting Domain Death Agonist Protein--genetics<br/>Bcl-2-Like Protein 11<br/>Cell Line, Tumor<br/>Cohort Studies<br/>ErbB Receptors--antagonists & inhibitors<br/>Female<br/>Humans<br/>Lung Neoplasms--drug therapy<br/>Membrane Proteins--biosynthesis<br/>Mice<br/>Mice, Nude<br/>Oncogenes<br/>Phosphatidylinositol 3-Kinases--genetics<br/>Phosphoinositide-3 Kinase Inhibitors<br/>Protein Kinase Inhibitors--pharmacology<br/>Proto-Oncogene Proteins--biosynthesis<br/>Receptor, ErbB-2--antagonists & inhibitors<br/>Retrospective Studies<br/>Signal Transduction--drug effects